Reuters logo
BRIEF-Nymox reports successful new phase 3 long-term Fexapotide repeat injection BPH trial results
2016年10月11日 / 下午2点07分 / 1 年前

BRIEF-Nymox reports successful new phase 3 long-term Fexapotide repeat injection BPH trial results

Oct 11 (Reuters) - Nymox Pharmaceutical Corp

* Nymox reports successful new phase 3 long-term fexapotide repeat injection bph trial results: lasting symptomatic improvement up to 6 years after single repeated treatment

* Nymox pharmaceutical - Results show there was long-term statistically significant symptomatic improvement compared to phase 3 patients who received placebo alone Source text for Eikon: Further company coverage:

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below